Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor
Total Page:16
File Type:pdf, Size:1020Kb
Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor To the extentstatements contained in this presentation are not descriptionsof historical facts regarding Kite Pharma, Inc. (“Kite,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward- looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success, cost and timing of our product development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research and development activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19 and any other product candidates; (iv) our ability to obtain funding for our operations and further development and commercialization of our product candidates; (v) our plans to research and discover additional product candidates, including through our acquired subsidiary in Amsterdam; (vi) our ability to develop, manufacture and commercialize our product candidates; (vii) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (viii) the rate and degree of market acceptance of our product candidates; (ix) our ability to attract and retain key scientific or management personnel; (x) the anticipated timing of clinical data availability; and (xi) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, includingwithout limitationin its Form10-Qforthe quarter ended March 31, 2015. Except as required by law,we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any suchstate or jurisdiction. 2 2 KITE PHARMA, INC. 30 Years of Cancer Cellular Immunotherapy 2015 2005 Before Treatment 6 Months After 1995 1985 Before After Treated with anti-CD19 CAR Treated with LAK cells + IL-2 3 3 KITE PHARMA, INC. Dramatic Response with Anti-CD19 CAR Before Treatment Post Treatment A patient with recurrent DLBCL post-SCT treated with anti-CD19 CAR T cells Ongoing Complete Response 15+ months in a patient with chemo-refractory PMBCL 4 4 Scans from Dr. Rosenberg NCI KITE PHARMA, INC. Kite is Redefining Cancer Therapy with Gene-based Cellular Immunotherapy • Corporate Headquarters in Santa Monica, CA and EU R&D facility in Amsterdam, NL • First product, KTE-C19 projected to launch in 2017 • Robust pipeline of Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) products with multiple products in clinical trials • Strong IP Estate for CAR and TCR products • Ongoing Response 4+ years in a Strategic partnerships providing access to patient with Follicular Lymphoma targets, technologies and faster time to human POC data • Proprietary, low-cost and rapid manufacturing process 5 5 KITE PHARMA, INC. Experienced Senior Leadership with Proven Track Records for Success Arie Belldegrun, MD, FACS Founder, Chairman, President, CEO Cynthia M. Butitta, MBA COO and CFO David D. Chang, MD, PhD CMO and EVP, R&D Helen S. Kim, MBA EVP, Business Development Margo R. Roberts, PhD Chief Scientific Officer Ton N. M. Schumacher, PhD Chief Scientific Officer, Kite EU 6 6 KITE PHARMA, INC. Scientific Advisory Board: World Leaders in Cancer Immunotherapy Owen Witte, MD – Chair Ronald Levy, MD • Distinguished Professor of Microbiology, • Robert K. Summy and Helen K. Summy Immunology and Molecular Genetics, UCLA Professor of Medicine, Stanford University • Howard Hughes Investigator • Director, Lymphoma Program, Stanford • Member, National Academy of Sciences University • Member, National Academy of Sciences James Economou, MD, PhD Antoni Ribas, MD, PhD • Professor of Surgery, Microbiology, • Director, Tumor Immunology Program, Immunology and Molecular Genetics and Jonsson Comprehensive Cancer Center, Molecular and Medical Pharmacology, UCLA UCLA • Professor of Medicine, Professor of • Vice Chancellor of Research, UCLA Surgery and Professor of Molecular and Medical Pharmacology, UCLA Donald Kohn, MD Inder Verma, PhD • Professor of Microbiology, Immunology and • Irwin and Joan Jacobs Chair of Exemplary Molecular Genetics & Pediatric Science and American Cancer Society Hematology/Oncology, UCLA Professor of Molecular Biology, The Salk • Director, Human Gene and Cell Therapy Institute Program, UCLA • Member, National Academy of Sciences • Member, Broad Stem Cell Research Center & Jonsson Comprehensive Cancer Center 7 7 KITE PHARMA, INC. Building a Robust IP Estate with Scientific Leaders in Gene-Based Cellular Immunotherapy Steven Rosenberg, MD, PhD • Chief of Surgery, NCI • Professor of Surgery, Uniformed Services University of Health Sciences and George Washington University School of Medicine and Health Sciences Clinical Pioneer Clinical Margo R. Roberts, PhD • Chief Scientific Officer, Kite Pharma, Inc. • Inventor on 16 US patents and patent applications related to CAR T cell technology and tumor vaccine therapies Zelig Eshhar, PhD Inventors (Member, Kite Scientific Advisory Board) • Chairman of Immunology Research, Sourasky Medical Center, Tel Aviv • Professor Emeritus, Weizmann Institute of Science, Israel 8 8 KITE PHARMA, INC. Expanding Pipeline Through Strategic Collaborations and Internal R&D CRADA • Pioneering research/pipeline • Product & process design • Early clinical evaluation Fully Integrated Company •9 clinical programs •Technology platform •US and EU R&D capabilities •Clinical and commercial manufacturing Strategic Collaboration • Rights to Next Generation TCR • Access to Manufacturing • Early clinical evaluation 9 9 KITE PHARMA, INC. Engineered Autologous T Cell Therapy (eACT™) Elegant Science, Streamlined Manufacturing 1. Cell Harvest 2. Patient Conditioning 3. Single CAR Cell Infusion 10 10 Kochenderfer and Rosenberg, Nature Reviews Clinical Oncology, 2013 KITE PHARMA, INC. Multiple CAR and TCR programs in Clinical Testing PROGRAM INDICATION PRE-IND PHASE 1 PHASE 2/3 Anti-CD19 CAR B Cell Malignancies NHL (DLBCL) NHL (MCL) Pivotal studies across 4 KTE-C19 CAR CLL indications in 2015 ALL EGFRvIII CAR Glioblastoma NY-ESO-1 TCR Solid tumors MAGE A3/A6 TCR Solid tumors MAGE A3 TCR Solid tumors HPV-16 E6 TCR Cervical and Head & Neck Cancer HPV-16 E7 TCR SSX2 TCR Solid tumors Heme Malignancy Neo-Antigen TCRs Solid Tumors Solid Tumors Amgen Heme Malignancies Collaboration and Solid Tumors 11 11 Other than the KTE-C19 and Amgen related programs, the clinical trials are being conducted by the NCI pursuant to our CRADA. KITE PHARMA, INC. IP Portfolio of Greater than 100 Patent Assets Worldwide* Broad CAR IP Proprietary CARs Proprietary TCRs Proprietary scFvs Proprietary Manufacturing Techniques Proprietary T-Cell Selection Techniques 12 12 *Includes in-house and in-licensed granted patents and pending patent applications KITE PHARMA, INC. Kite CAR & TCR Platforms Redirecting Immune Cells Against Cancer Chimeric Antigen Receptor (CAR) Products T Cell Receptor (TCR) Products Targets molecules Targets molecules on the cell at or below the surface cell surface 13 13 KITE PHARMA, INC. TCR Platform Provides Access to a Broad Spectrum of Therapeutic Tumor Targets Potential CAR targets (~27% Human Proteome) Potential TCR targets (~73% Human Proteome) Sallman et al, BMC Biology (2009) 14 14 KITE PHARMA, INC. Franchise Approach to TCR Platform and Pipeline NY-ESO-1 SSX2 Cancer • Uniquely expressed only on Testis cancer cells Antigens MAGE A3 MAGE A3/A6 Targets • Viral antigens are unique Viral HPV-16 E6 HPV-16 E7 Antigens • High-risk oncogenic viruses Neo- • Specific to a patient’s own Personalized antigens tumor Proprietary Platform Allowing Rapid, High-throughput Identification of TCR-Based Product Candidates 15 15 KITE PHARMA, INC. TCF Acquisition Expands TCR Product Pipeline in Solid Tumors HIGHLIGHTS OF ACQUISITION • TCR-GENErator™: industry-leading R&D engine for rapid, high-throughput identification of TCR-based product candidates, which could enter the clinic as early as 2017. • NKI Relationship: provides important operational platform, access to investigators, clinical sites and manufacturing facilities in Europe. • Professor Dr. Schumacher: preeminent scientist in immunotherapy to lead Kite Pharma EU as CSO • European presence 16 16 KITE PHARMA, INC. Actively Investigating CARs and TCRs that Target Multiple Tumor Types TARGET TUMOR TYPES CD19